How much revenue did Amgen generate this year?
Amgen has achieved a revenue of 33.68 B USD this year.
Amgen Revenue 2024
Amgen Revenue
33.68 B USD
Amgen Dividend yield
3.12 %
Ticker
AMGN
ISIN
US0311621009
WKN
867900
In 2024, Amgen's sales reached 33.68 B USD, a 19.48% difference from the 28.19 B USD sales recorded in the previous year.
The Amgen Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 35.11 | 56,32 |
| 2028e | 34.95 | 56,59 |
| 2027e | 34.68 | 57,03 |
| 2026e | 35.73 | 55,35 |
| 2025e | 34.84 | 56,76 |
| 2024e | 33.68 | 58,71 |
| 2023 | 28.19 | 70,15 |
| 2022 | 26.32 | 75,66 |
| 2021 | 25.98 | 75,16 |
| 2020 | 25.42 | 75,77 |
| 2019 | 23.36 | 81,35 |
| 2018 | 23.75 | 82,73 |
| 2017 | 22.85 | 82,19 |
| 2016 | 22.99 | 81,90 |
| 2015 | 21.66 | 80,49 |
| 2014 | 20.06 | 77,96 |
| 2013 | 18.68 | 82,08 |
| 2012 | 17.27 | 81,47 |
| 2011 | 15.58 | 82,62 |
| 2010 | 15.05 | 85,25 |
| 2009 | 14.64 | 85,72 |
| 2008 | 15 | 84,70 |
| 2007 | 14.77 | 82,75 |
| 2006 | 14.27 | 85,32 |
| 2005 | 12.43 | 83,25 |
| 2004 | 10.55 | 83,59 |
Amgen Aktienanalyse
What does Amgen do?
Amgen Inc. is a global biotechnology company focused on the development and production of pharmaceuticals. It was founded in 1980 by William K. Bowes Jr. and George B. Rathmann in Thousand Oaks, California/USA. The founders had the vision to create new treatment options for serious diseases such as cancer, autoimmune diseases, and osteoporosis. Amgen faced difficulties in its early days due to limited financial resources and setbacks in research. However, the company succeeded in developing the first recombinant therapeutic protein drug, Erythropoietin (EPO), and bringing it to the market. Today, Amgen has become one of the largest biotechnology companies in the world with over 24,000 employees worldwide. The company is known for its research and development work in oncology, kidney diseases, blood disorders, inflammation, and bone diseases. Amgen's business model involves investing in research and development to develop new drugs and commercialize them in global markets. The company follows a "biological platform" strategy, focusing on biotechnology products based on proteins and antibodies. Amgen has several product lines, including Biologics, Biosimilars, and Small Molecules. Biologics are protein-based drugs manufactured using living cells. Biosimilars are products that have similar structures to existing biologics. Small Molecules are chemically manufactured drugs. Some of Amgen's most well-known products include Epogen and Aranesp (both Erythropoietin-releasing hormones), Neulasta and Neupogen (both granulocyte colony-stimulating factors), Enbrel (a TNF inhibitor for the treatment of rheumatoid arthritis), Prolia and Xgeva (both Denosumab inhibitors for the treatment of osteoporosis), and Blincyto (a bispecific antibody against cancer). Amgen is also involved in cancer immunotherapy and has a range of medications in its portfolio, including a CAR-T immunotherapy used for certain forms of acute lymphoblastic leukemia (ALL). In addition, Amgen specializes in the development of biosimilars. In 2017, the company introduced six biosimilars to the market, including copies of Enbrel and Humira for the treatment of rheumatoid arthritis. Biosimilars have the potential to reduce the costs of patient treatment as they are typically cheaper than the original products. Furthermore, Amgen works closely with other companies and research institutions to develop innovative products and technologies. The company has numerous partnerships and licensing agreements with other companies in the biotech industry to accelerate its growth and expand its product pipeline. Overall, Amgen has successfully established itself as one of the leading biotechnology companies in the world. It is known for its innovative products, investments in research and development, and partnerships with other companies. With its wide product portfolio and commitment to producing high-quality biological products, Amgen will continue to play an important role in the healthcare industry. Amgen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Amgen revenue by segment
In the annual report of the Amgen share (US0311621009, 867900, AMGN), it breaks down its revenues into 2 segments: 1. Human Therapeutics, 2. Other. The Amgen stock (WKN: 867900, ISIN: US0311621009, Ticker Symbol: AMGN) is a leading investment for investors interested in participating in the Health Care sector.
Revenue Details
Understanding Amgen's Sales Figures
The sales figures of Amgen originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Amgen’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Amgen's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Amgen’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Amgen Stock
How much was the turnover of the company Amgen compared to the previous year?
The revenue of Amgen has increased by 19.48% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Amgen?
The revenue of Amgen is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Amgen measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Amgen so important for investors?
The revenue of Amgen is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Amgen pay?
Over the past 12 months, Amgen paid a dividend of 8.52 USD . This corresponds to a dividend yield of about 3.12 %. For the coming 12 months, Amgen is expected to pay a dividend of 14.1 USD.
What is the dividend yield of Amgen?
The current dividend yield of Amgen is 3.12 %.
When does Amgen pay dividends?
Amgen pays a quarterly dividend. This is distributed in the months of September, December, March, June.
How secure is the dividend of Amgen?
Amgen paid dividends every year for the past 19 years.
What is the dividend of Amgen?
For the upcoming 12 months, dividends amounting to 14.1 USD are expected. This corresponds to a dividend yield of 5.16 %.
In which sector is Amgen located?
Amgen is assigned to the 'Health' sector.
Wann musste ich die Aktien von Amgen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Amgen from 6/7/2024 amounting to 2.25 USD, you needed to have the stock in your portfolio before the ex-date on 5/16/2024.
When did Amgen pay the last dividend?
The last dividend was paid out on 6/7/2024.
What was the dividend of Amgen in the year 2023?
In the year 2023, Amgen distributed 7.76 USD as dividends.
In which currency does Amgen pay out the dividend?
The dividends of Amgen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Amgen stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank
Andere Kennzahlen von Amgen
Our stock analysis for Amgen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amgen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
